Molecular Partners Ag MOLN
NASDAQ MOLN
$4.18 -0.17 (-3.76%)
As of: Sep 10, 2026 · 9:51 AM EDT

Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026)

Molecular Partners Ag's (MOLN) quarterly Non-Current Assets came in at $5.4 million in Q2 2026, up 21.23% year-over-year from $4.5 million in Q2 2025, and down 10.64% quarter-over-quarter from $6.0 million in Q1 2026.

Analysis

Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026) Analysis & Trends

Molecular Partners Ag (MOLN) has reported Non-Current Assets for 7 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Non-Current Assets rose 21.23% year-over-year to $5.4 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 21.23% increase from a year earlier, with the FY2025 full-year figure at $6.3 million, up 30.69% from the prior year.
  • Non-Current Assets was $5.4 million for Q2 2026 at Molecular Partners Ag, down from $6.0 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $8.9 million in Q1 2022 and troughed at $4.0 million in Q3 2025.
  • A 5-year average of $6.3 million and a median of $6.4 million in 2025 frame the typical range for Non-Current Assets.
  • Across the five-year window, Non-Current Assets slipped 27.03% in 2024 and soared 35.0% in 2025, its largest moves.
  • Over 5 years, Non-Current Assets stood at $7.8 million in 2022, then fell by 14.73% to $6.6 million in 2023, then decreased by 27.03% to $4.8 million in 2024, then soared by 35.0% to $6.5 million in 2025, then declined by 17.53% to $5.4 million in 2026.
  • The last three Non-Current Assets figures came in at $5.4 million (Q2 2026), $6.0 million (Q1 2026), and $6.5 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 1.96 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 564.41 Mn
10 Molecular Partners Ag 156.54 Mn 156.54 Mn - 5.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.40 Mn
Mar 31, 2026 6.04 Mn
Dec 31, 2025 6.54 Mn
Sep 30, 2025 3.99 Mn
Jun 30, 2025 4.45 Mn
Mar 31, 2025 4.61 Mn
Dec 31, 2024 4.85 Mn
Sep 30, 2024 5.40 Mn
Jun 30, 2024 5.54 Mn
Mar 31, 2024 6.21 Mn
Dec 31, 2023 6.64 Mn
Sep 30, 2023 7.00 Mn
Jun 30, 2023 7.38 Mn
Mar 31, 2023 7.63 Mn
Dec 31, 2022 7.79 Mn
Sep 30, 2022 7.74 Mn
Jun 30, 2022 8.11 Mn
Mar 31, 2022 8.92 Mn
Dec 31, 2021 9.19 Mn
Sep 30, 2021 9.49 Mn